Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Por um escritor misterioso
Descrição
New Drugs on the Block—Emerging Treatments for Nonalcoholic
Cancers, Free Full-Text
PDF) Discovery and Optimization of Imidazopyridine-based
TP-020 (MGAT2-IN-1), MGAT2 Inhibitor
Pharmacotherapies of NAFLD: updated opportunities based on
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
PDF) The Discovery and Pharmacology of a Novel Class of
NASH Target Development Service for DAG O-Acyltransferase (DGAT
Pharmacotherapies of NAFLD: updated opportunities based on
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
Therapeutic Strategies for Metabolic Diseases: Small‐Molecule
The effect of CpdB on diabetes and obesity in HFD‐fed ob/ob mice
Updates on novel pharmacotherapeutics for the treatment of
Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the
The monoacylglycerol acyltransferase pathway contributes to
de
por adulto (o preço varia de acordo com o tamanho do grupo)
